Merck May Be Positioned For First Approval Of A Protease Inhibitor In HCV
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharma announced Jan. 6 that boceprevir has been accepted for priority review by FDA, making an early-May action date likely.
You may also be interested in...
Dual FDA Advisory Committee Reviews Shaping Up To Be A Showdown For Dueling Merck And Vertex Hepatitis C Drugs
Approval is widely assumed for both boceprevir and telaprevir, but there is still much to be discussed about the devilish details. Additional data coming out at European liver meeting should also be informative.
Dual FDA Advisory Committee Reviews Shaping Up To Be A Showdown For Dueling Merck And Vertex Hepatitis C Drugs
Approval is widely assumed for both boceprevir and telaprevir, but there is still much to be discussed about the devilish details. Additional data coming out at European liver meeting should also be informative.
Vertex Expects Shorter Duration Of Therapy Will Give Telaprevir Long Reign Atop Market
With high SVR rate and quad therapy showing potential for 12-week treatment period, telaprevir may enjoy short- and long-term market success.